USD10
SRPT Anteile
Über Sarepta TherapeuticsSarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
USD10
SRPT Anteile
Über Sarepta TherapeuticsSarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Statistiken
TRADINGFENSTER
Geschlossen
ÖFFNET AM
Nicht genügend Daten
MARKTKAPITALISIERUNG
1,77 Mrd. $
ERÖFFNUNGSPREIS
16,68 $
TIEF (1 J)
10,42 $
HOCH (1 J)
76,67 $
TIEF (24 STD.)
16,53 $
HOCH (24 STD.)
17,33 $
VOLUMEN (24 STD.)
2,86 Mio. $
1,85 %
Kursverlauf
Time | Price | Change |
|---|---|---|
Heute | 16,68 $ | |
1 Tag | 16,69 $ | |
1 Woche | 16,50 $ | |
1 Monat | 18,56 $ | |
1 Jahr | 76,33 $ |